Navidea Biopharmaceuticals Stock Current Liabilities
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Navidea Biopharmaceutica's long-term financial health and intrinsic value.
Navidea |
Navidea Biopharmaceuticals Company Current Liabilities Analysis
Navidea Biopharmaceutica's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Navidea Biopharmaceutica Current Liabilities | 6.18 M |
Most of Navidea Biopharmaceutica's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Navidea Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Navidea Biopharmaceuticals has a Current Liabilities of 6.18 M. This is 99.65% lower than that of the Biotechnology sector and 98.86% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.92% higher than that of the company.
Navidea Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Navidea Biopharmaceutica's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Navidea Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Navidea Biopharmaceutica by comparing valuation metrics of similar companies.Navidea Biopharmaceutica is currently under evaluation in current liabilities category among its peers.
Navidea Fundamentals
| Return On Equity | -11.0 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 3.5 M | ||||
| Shares Outstanding | 100.08 M | ||||
| Shares Owned By Insiders | 35.43 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 2.69 M | ||||
| Price To Earning | 0.53 X | ||||
| Price To Book | 8.16 X | ||||
| Price To Sales | 84.14 X | ||||
| Revenue | 65.65 K | ||||
| Gross Profit | (119.3 K) | ||||
| EBITDA | (14.05 M) | ||||
| Net Income | (15.18 M) | ||||
| Cash And Equivalents | 328.01 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.43 M | ||||
| Debt To Equity | 1.20 % | ||||
| Current Ratio | 0.22 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (8.99 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 8.04 M | ||||
| Total Asset | 4.37 M | ||||
| Retained Earnings | (388 M) | ||||
| Working Capital | (6.74 M) | ||||
| Current Asset | 12.58 M | ||||
| Current Liabilities | 6.18 M | ||||
| Net Asset | 4.37 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |